A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Phase 2 – studying effectiveness and dosage
Conditions:
Severe Hypertriglyceridemia
Sponsor: Eli Lilly and Company
trial.available_in:
БГ
Overview
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Who can participate
Inclusion Criteria:
* History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history
* Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart)
* Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive)
Exclusion Criteria:
* Have had a major atherosclerotic cardiovascular event within the past 3 months prior to screening
* Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome
* Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral vector-mediated, or other genetic modification techniques
* Have a history of chronic alcohol abuse within 3 years prior to screening
БГ